Before pharmacists at UC Davis Health implemented a streamlined process to approve and institute cell and gene therapy (CGT) treatments for patients, the procedure was somewhat disjointed due to product sourcing, contracting, payor authorization and the logistics of administration.
Traditionally, the pharmacy and therapeutics (P&T) committee didn’t necessarily review therapies until the FDA approved them, communication between departments was limited, and the